Stock listing
OTC:VINC Vincerx Pharma Inc Stock
Follow Vincerx Pharma Inc into a list and get an email when it puts out news.
Share price · OTC:VINC
$0.016 USD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.016 – $0.016 USDNov 20, 2026
- Volume
- 479 sharesNov 20, 2026
- Market cap
- $83,748 USDAt the close on Nov 20, 2026 · price × 5.23M shares outstanding
- 52-week range
- $0.010 – $0.026 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $24 USDMedian day 500 shares · last 3 months, Aug 26, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 26, 2026 – Nov 20, 2026 · OTC:VINC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.016 | 0.000 | 0.0% | $0.016 | $0.016 | $0.016 | 479 | |
| $0.016 | +0.001 | +6.7% | $0.016 | $0.016 | $0.016 | 1,216 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 663 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 5,500 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 2,111 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 177 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 1,070 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 1,870 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 428 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 1,000 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 175 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 2,205 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 251 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 460 | |
| $0.015 | -0.011 | -41.6% | $0.015 | $0.015 | $0.015 | 1 | |
| $0.026 | +0.011 | +71.3% | $0.015 | $0.026 | $0.015 | 10,977 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 101 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 104 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 801 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 200 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 500 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 1,029 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 250 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 254 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 1,682 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 1,784 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 340 | |
| $0.015 | 0.000 | 0.0% | $0.015 | $0.015 | $0.015 | 365 | |
| $0.015 | +0.002 | +14.5% | $0.015 | $0.015 | $0.015 | 151 | |
| $0.013 | 0.000 | 0.0% | $0.013 | $0.013 | $0.013 | 614 | |
| $0.013 | +0.000 | +3.1% | $0.013 | $0.013 | $0.013 | 8,000 | |
| $0.013 | 0.000 | 0.0% | $0.013 | $0.013 | $0.013 | 385 | |
| $0.013 | 0.000 | 0.0% | $0.013 | $0.013 | $0.013 | 733 |
Splits
1 split · OTC:VINC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- OTC:VINC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Vincerx Pharma Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 2 decks · latest Jan 23, 2025
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.69
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Vincerx Pharma Inc · OTC:VINC | US$83,748 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.69 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,500 | −US$4,070 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| Median of the others | US$192,289 | US$73,510 | 1.2× | 18.5× | 0.2× | −382.1% | 0.0× | 1.14 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2025 | May 12, 2025 · Before open | +4.4% |
| Q4 2024 | Mar 27, 2025 · After close | −4.8% |
| Q3 2024 | Nov 12, 2024 · Before open | −3.5% |
| Q2 2024 | Aug 8, 2024 · After close | −7.5% |
| Q1 2024 | May 14, 2024 · After close | −2.2% |
| Q4 2023 | Mar 29, 2024 · After close | +15.6% |
| Q3 2023 | Nov 14, 2023 · Before open | −9.0% |
| Q2 2023 | Aug 7, 2023 · Before open | −2.2% |
| Q1 2023 | May 11, 2023 · After close | −1.8% |
| Q4 2022 | Mar 28, 2023 · After close | +7.4% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2022 | Nov 10, 2022 · After close | −10.2% |
| Q2 2022 | Aug 11, 2022 · After close | +6.8% |
| Q1 2022 | May 12, 2022 · After close | −6.1% |
| Q4 2021 | Mar 29, 2022 · Before open | −5.0% |
| Q3 2021 | Nov 12, 2021 · Before open | −0.7% |
| Q2 2021 | Aug 12, 2021 · After close | +10.5% |
| Q1 2021 | May 17, 2021 · Before open | −2.6% |
| Q4 2020 | Mar 22, 2021 · Before open | −3.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (January 2025) | Merger or acquisition | 23 slides | Jan 23, 2025 |
| LifeSci Acquisition — SPAC Merger (September 2020) | SPAC merger | 35 slides | Sep 29, 2020 |
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 1.09M | 915.0K | 939.0K | 340.0K | 173.0K | 173.0K |
| Gross profit | -1.09M | -915.0K | -939.0K | -340.0K | -173.0K | -173.0K |
| Research and development | 15.5M | 28.1M | 52.2M | 40.1M | 7.12M | |
| Selling, general and administrative | 16.0M | 13.6M | 19.0M | 22.6M | 3.60M | 54.0K |
| Operating income | -31.5M | -42.6M | -68.7M | -62.7M | -10.7M | -45.0K |
| Depreciation and amortization | 1.09M | 915.0K | 939.0K | 340.0K | 20.0K | 54.0K |
| EBITDA | -30.4M | -41.7M | -67.8M | -62.3M | -10.7M | 9.00K |
| Interest expense | 8.21M | 23.4M | 8.00K | 0 | ||
| Income before tax | -30.1M | -40.2M | -63.0M | -39.3M | -10.7M | -45.0K |
| Income tax | -8.21M | -23.7M | 8.00K | -54 | ||
| Net income | -30.1M | -40.2M | -65.4M | -39.3M | -10.7M | -54.0K |
| Earnings per share, basic | -5.75 | -6.84 | -11.27 | -8.30 | -7.53 | -0.04 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 4.99M | 12.8M | 11.7M | 111.5M | 61.8M | 684.7K |
| Short-term investments | 0 | 40.8M | 0 | |||
| Receivables | 1.04M | 1.04M | 1.37M | |||
| Inventory | -1.24M | |||||
| Current assets | 6.41M | 14.7M | 56.0M | 111.8M | 63.1M | 791.0K |
| Property, plant and equipment | 3.24M | 4.18M | ||||
| Total assets | 8.01M | 18.2M | 59.3M | 117.7M | 63.2M | 1.00K |
| Accounts payable | 2.03M | 2.50M | 4.07M | 2.02M | 491.0K | 35.0K |
| Current liabilities | 5.28M | 5.61M | 9.16M | 13.9M | 37.8M | 44.0K |
| Total debt | 2.50M | 3.44M | 4.17M | |||
| Total liabilities | 5.28M | 7.00M | 11.6M | 17.4M | 5.50M | 44.0K |
| Shareholders' equity | 2.72M | 11.2M | 47.7M | 100.3M | 25.4M | -44.0K |
| Shares outstanding | 5.23M | 5.87M | 5.80M | 4.74M | 1.42M | 1.43M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Cash from operations | -26.1M | -40.5M | -59.6M | -33.4M | -2.28M | -35.0K |
| Capital spending | 0 | 0 | 0 | -5.26M | -258.0K | -258.0K |
| Free cash flow | -26.1M | -40.5M | -59.6M | -38.7M | -2.28M | -35.0K |
| Cash from investing | 212.0K | 41.5M | -40.6M | -5.26M | -65.6M | -65.6M |
| Cash from financing | 18.0M | 114.0K | 280.0K | 88.5M | 64.1M | 66.5M |
| Share buybacks | 1.00K | |||||
| Change in cash | -7.79M | 1.12M | -99.8M | 49.8M | 61.8M | 790.0K |
Cap table
Built by 6ix from Vincerx Pharma Inc’s releases
- Common shares
- 5,234,277
- Fully diluted
- 5,234,277
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,234,277 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,234,277 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ahmed Hamdy Other companies: Curis, Inc. (Chief Medical Officer · Since at least May 1, 2025) | Chief Executive Officer, Director · Jun 29, 2021 – Aug 12, 2024 · Past |
| Francisco Salva Other companies: Azitra Inc (President and CEO · Since at least Jun 15, 2023) | Director · May 13, 2021 – May 23, 2024 · Past |
| Hermes de Jesus Garban | Chief Medical Officer · Mar 1, 2021 – Feb 14, 2022 · Past |
| Kevin Haas | Acting Chief Financial Officer · Dec 20, 2024 – Dec 20, 2024 · Past |
| Sooin Hwang | Chief Business Officer · May 13, 2021 – Feb 14, 2022 · Past |
Log in to ask 6ix AI your own questions about Vincerx Pharma Inc.